B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases

Immunobiology

Volumn 216, Issue 1-2, 2011, Pages 173-183

  Zagon, Ian S ^a   Donahue, Renee N ^a   Bonneau, Robert H ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Met5 enkephalin; Cell proliferation; Cyclin dependent kinase inhibitor; OGFr; Opioid growth factor; T lymphocyte

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DELTA OPIATE RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; KAPPA OPIATE RECEPTOR; LIPOPOLYSACCHARIDE; MU OPIATE RECEPTOR; MYELIN; NALTREXONE; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; PROTEIN P16; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL COUNT; CONTROLLED STUDY; FEMALE; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OLIGODENDROGLIA; PARACRINE SIGNALING; PRIORITY JOURNAL;

ANIMALS; B-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENKEPHALIN, METHIONINE; IMMUNOSUPPRESSION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NALTREXONE; RECEPTORS, OPIOID; RNA, SMALL INTERFERING;

EID: 78649496647     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.06.001     Document Type: Article

References (61)

1. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev. 2009, 8:410-414.
2. Akil H., Watson S.J., Young E., Lewis M.E., Katchuturian H., Walter J.M. Endogenous opioids: biology and function. Ann. Rev. Neurosci. 1984, 7:223-255.
3. Balague C., Kunkel S.L., Godessart N. Understanding autoimmune disease: new targets for drug discovery. Drug Discov. Today 2009, 14:926-934.
4. Behar O.Z., Ovadia H., Polakiewicz R.D., Abramsky O., Rosen H. Regulation of proenkephalin A messenger ribonucleic acid levels in normal B lymphocytes: specific inhibition by glucocorticoid hormones and superinduction by cycloheximide. Endocrinology 1991, 129:649-655.
5. Blebea J., Mazo J.E., Kihara T., Vu J.H., McLaughlin P.J., Atnip R.G., Zagon I.S. Opioid growth factor modulates angiogenesis. J. Vascular Surg. 2000, 32:364-373.
6. Carr D.J., Rogers T.J., Weber R.J. The relevance of opioids and opioid receptors on immumocompetence and immune homeostasis. Proc. Soc. Exp. Biol. Med. 1996, 213:248-257.
7. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol. Cancer 2007, 7:5-17.
8. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp. Biol. Med. 2009, 234:532-541.
9. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 2009, 1:319-327.
10. Cheng F., Zagon I.S., Verderame M.F., McLaughlin P.J. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res. 2007, 67:10511-10518.
11. 5]-enkephalin differentially affect IgM and IgG production by B cells. J. Neuroimmunol. 1997, 73:37-46.
12. Dass C., Mahalakshmi P. Phosphorylation of enkephalins enhances their proteolytic stability. Life Sci. 1996, 58:1039-1045.
13. Davidson A., Diamond B. Autoimmune diseases. N. Engl. J. Med. 2001, 345:340-350.
14. Donahue R.D., McLaughlin P.J., Zagon I.S. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1716-R1725.
15. Dornair K., Meinl E., Hohfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells. Sem. Immunopathol. 2009, 31:467-477.
16. Dörner T., Jacobi A.M., Lipsky P.E. B cells in autoimmunity. Arthritis Res. Ther. 2009, 11:247.
17. Fraussen J., Vrolix K., Martinez-Martinez P., Losen M., De Baets M.H., Stinissen P., Somers V. B cells characterization and reactivity analysis in multiple sclerosis. Autoimmun. Rev. 2009, 8:654-658.
18. 5]enkephalin administration. Eur. J. Pharmacol. 2000, 392:101-108.
19. Gilman S.C., Schwartz J.M., Milner R.J., Bloom F.E., Feldman J.D. β-Endorphin enhances lymphocyte proliferative responses. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:4226-4230.
20. Hytrek S.D., McLaughlin P.J., Lang C.M., Zagon I.S. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett. 1996, 101:159-164.
21. Jankovic B.D., Maric D. Enkephalins and immunity. I. In vitro suppression and potentiation of humoral immune response. Ann. NY Acad. Sci. 1987, 496:115-125.
22. Johnson H.M., Smith E.M., Torres B.A., Blalock J.E. Regulation of the in vitro antibody response by neuroendocrine hormones. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:4171-4174.
23. 5]enkephalin fragments. Eur. J. Pharmacol. 1998, 347:95-99.
24. Kuis W., Villiger P.M., Leser H.G., Lotz M. Differential processing of proenkephalin-A by human peripheral blood monocytes and T lymphocytes. J. Clin. Invest. 1991, 88:817-824.
25. Lapointe R., Bellemare-Pelletier A., Housseau A.F., Thibodeau J., Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003, 63:2836-2843.
26. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001, 62:111-123.
27. McLaughlin P.J., Jaglowski J.R., Verderame M.F., Stack B.C., Leure-duPree A.E., Zagon I.S. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int. J. Oncol. 2005, 26:809-816.
28. McLaughlin P.J., Kreiner S., Morgan C.R., Zagon I.S. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int. J. Oncol. 2008, 33:751-757.
29. Morgan E.L., McClurg M.R., Janda J.A. Suppression of human B lymphocyte activation by β-endorphin. J. Neuroimmunol. 1990, 28:209-217.
30. Nair A., Bonneau R.H. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 2006, 171:72-85.
31. Noda M., Furutani Y., Takashashi H., Toyosato M., Hirose T., Inayama S., Nakanishi S., Numa S. Cloning and sequencing analysis of cDNA for bovine adrenal preproenkephalin. Nature 1982, 295:202-206.
32. g7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet β cells of nonobese diabetic mice. J. Immunol. 1999, 163:743-750.
33. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
34. Peterson P.K., Molitor T.W., Chao C.C. The opioid-cytokine connection. J. Neuroimmunol. 1998, 83:63-69.
35. Rivera A., Chen C.C., Ron N., Dougherty J.P., Ron Y. Role of B cells as antigen-presenting cells in vivo revisted: antigen-specific B cells are essential for T cell expansion in lymph nodes and for system T cell responses to low antigen concentrations. Int. Immunol. 2001, 13:1583-1593.
36. Rosen H., Behar O., Abramsky O., Ovadia H. Regulated expression of proenkephalin A in normal lymphocytes. J. Immunol. 1989, 143:3703-3707.
37. Roth K.A., Lorenz R.G., Unanue R.A., Weaver C.T. Nonopiate active proenkephalin-derived peptides are secreted by T helper cells. FASEB J. 1989, 3:2401-2407.
38. Salzet M., Tasiemski A. Involvement of pro-enkephain-derived peptides in immunity. Dev. Comp. Immunol. 2001, 25:177-185.
39. Serrez D.V., Silveira P.A. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr. Dir. Autoimmun. 2003, 6:212-227.
40. Sharp B.M., Roy S., Bidlack J.M. Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 1998, 83:45-56.
41. Shlomchik M.J. Activating system autoimmunity: B's, T's, and tolls. Curr. Opin. Immunol. 2009, 21:626-633.
42. Smith J.P., Bingaman S.I., Mauger D.T., Harvey H.A., Demers L.M., Zagon I.S. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J. Clin. Trials 2010, 2:37-48.
43. Smith J.P., Conter R.L., Bingaman S.I., Harvey H.A., Mauger D.T., Ahmad M., Demers L.M., Stanley W.B., McLaughlin P.J., Zagon I.S. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti-Cancer Drugs 2004, 15:203-209.
44. Smith J.P., Stock H., Bingaman S.I., Mauger D.T., Rogosnitzky M., Zagon I.S. Low-dose naltrexone therapy improves active Crohn's disease. Am. J. Gastroenterol. 2007, 102:820-828.
45. Soder O., Hellstrom P.M. Neuropeptide regulation of human thymocyte, guinea pig T lymphocyte and rat B lymphocyte mitogenesis. Int. Arch. Allergy Appl. Immunol. 1987, 84:205-211.
46. Tsirogianni A., Pipi E., Soufleros K. Specificity of islet cell autoantibodies and coexistense with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun. Rev. 2009, 8:687-691.
47. van den Bergh P., Rozing J., Nagelkerken L. Identification of two moieties of β-endorphin with opposing effects on T-cell proliferation. Immunology 1993, 79:18-23.
48. 5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin. Cell Prolif. 2000, 33:63-73.
49. Zagon I.S., Donahue R.N., McLaughlin P.J. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R1154-R1161.
50. Zagon I.S., Donahue R.N., Rogosnitzky M., McLaughlin P.J. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp. Biol. Med. 2008, 8:968-979.
51. Zagon I.S., Kreiner S., Heslop J.J., Conway A.B., Morgan C.R., McLaughlin P.J. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int. J. Oncol. 2008, 33:317-323.
52. Zagon I.S., McLaughlin P.J. Production and characterization of polyclonal and monoclonal antibodies to zeta (ζ) opioid receptor. Brain Res. 1993, 630:295-302.
53. Zagon I.S., McLaughlin P.J. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003, 37:79-88.
54. Zagon I.S., McLaughlin P.J. Opioid growth factor, opioids, and differentiation of human cancer cells. Neuropeptides 2005, 39:495-505.
55. Zagon I.S., Rahn K.A., Bonneau R.H., Turel A.P., McLaughlin P.J. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 2010, 1310:154-161.
56. Zagon I.S., Rahn K.A., McLaughlin P.J. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides 2007, 41:441-452.
57. Zagon I.S., Rahn K.A., Turel A.P., McLaughlin P.J. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp. Biol. Med. 2009, 234:1383-1392.
58. Zagon I.S., Ruth T.B., McLaughlin P.J. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat. Rec. A: Discov. Mol. Cell. Evol. Biol. 2005, 282:24-37.
59. Zagon I.S., Sassani J.W., Kane E.R., McLaughlin P.J. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res. 1997, 759:92-102.
60. Zagon I.S., Sassani J.W., Verderame M.F., McLaughlin P.J. Particle-mediated gene transfer of OGFr cDNA regulates cell proliferation of the corneal epithelium. Cornea 2005, 24:614-619.
61. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 2002, 38:351-376.